PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity
Authors:
- 14 August 2018
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 103 (10) , 3589-3592
Abstract
Context Immune checkpoint inhibitors, including monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand (PD-L1), have emerged as beneficial cancer immunotherapies. These therapies are known to cause immune-related side effects; however, their role in patients with a preexisting autoimmune disease is not clear. Case Description We describe two cases of anti-PD-1 immune-related adverse events. A 52-year-old male with longstanding type 1 diabetes (T1D), long-term stable kidney transplant, and hypothyroidism received two separate anti-PD-1 monoclonal antibodies for metastatic melanoma. The patient developed acute kidney graft rejection requiring hemodialysis and worsening of autoimmune hypothyroidism three weeks after starting treatment. He continued anti-PD-1 treatments and remained on hemodialysis and increased levothyroxine dosage. The second case is a 62-year-old male with no previous history of diabetes who received the anti-PD-1 treatment, and developed severe diabetic ketoacidosis (DKA) five days following the start of therapy. Further laboratory testing revealed high titer antibodies directed against glutamic acid decarboxylase, which were of the IgG isotype involved in memory immune responses, and likely present before anti-PD-1 treatment. He also had human leukocyte antigen genes that confer T1D genetic risk. Despite normal pre-treatment blood glucose levels and HbA1c, the patient has required permanent exogenous insulin treatment. Conclusion Patients with preexisting endocrine autoimmunity may have more frequent and severe immune-related side effects with anti-PD-1 treatment. Given the morbidity and mortality associated with solid organ transplant rejection and DKA, clinicians caring for patients receiving these state-of-the-art therapies need to be aware of the potential adverse events.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (DK108868, DK110845, DK032083)
This publication has 13 references indexed in Scilit:
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Increased Effector Memory Insulin-Specific CD4+ T Cells Correlate With Insulin Autoantibodies in Patients With Recent-Onset Type 1 DiabetesDiabetes, 2017
- Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved MechanismsThe Journal of Clinical Endocrinology & Metabolism, 2017
- Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathiesNature Reviews Endocrinology, 2017
- Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case reportCancer Immunology, Immunotherapy, 2016
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAnnals of Oncology, 2016
- Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanomaAnnals of Oncology, 2016
- Tumor Regression and Allograft Rejection after Administration of Anti–PD-1New England Journal of Medicine, 2016
- Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 DiabetesDiabetes Care, 2015
- Precipitation of Autoimmune Diabetes With Anti-PD-1 ImmunotherapyDiabetes Care, 2015